Business Context and Reporting Period
Company: Iovance Biotherapeutics, Inc. (IOVA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Iovance is a commercial-stage biopharmaceutical company focused on tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its commercial portfolio includes Amtagvi® (lifileucel), the first one-time, individualized T cell therapy for previously treated advanced melanoma, and Proleukin® (aldesleukin), an interleukin-2 product used in the Amtagvi regimen and other oncology applications. The company operates a centralized manufacturing facility, the Iovance Cell Therapy Center (iCTC), in Philadelphia.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 Value | 2024 Value | Change |
|---|---|---|---|
| Total Revenue | $263.5 million | $164.1 million | +61% |
| Amtagvi Revenue | $220.0 million | $103.6 million | +112% |
| Proleukin Revenue | $43.5 million | $60.5 million | -28% |
| Net Loss | $(391.0) million | $(372.2) million | -5% (Wider) |
| Cost of Sales | $173.2 million | $93.2 million | +86% |
| R&D Expenses | $300.3 million | $276.2 million | +9% |
| SG&A Expenses | $152.3 million | $152.3 million | Flat |
| Cash & Equivalents | $163.1 million | $115.7 million | +41% |
| Total Liquidity (Cash + Short-term Inv) | $303.0 million | $323.8 million | -6% |
| Operating Cash Flow | $(302.4) million | $(353.0) million | Improved by $50.6M |
Note: The filing text does not provide a specific gross margin percentage, but Cost of Sales increased significantly due to higher Amtagvi sales volume and inventory reserves.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 61% driven by a 112% surge in Amtagvi sales following its February 2024 FDA approval. This was partially offset by a 28% decline in Proleukin revenue, attributed to the depletion of initial distributor re-stocking demand seen in 2024.
- Cost Structure: Cost of sales rose 86% due to increased Amtagvi manufacturing costs, a $9.5 million increase in excess/obsolete inventory reserves (primarily Proleukin), and $18.1 million in period costs related to patient drop-offs and manufacturing failures.
- Restructuring: The company incurred $5.1 million in restructuring charges in 2025 (none in 2024) following an August 2025 strategic plan that reduced the workforce by approximately 19% to extend cash runway.
- Manufacturing Transition: The company completed the transition of all Amtagvi and lifileucel manufacturing to its internal iCTC facility. The agreement with contract manufacturer Minaris terminated in Q1 2026.
Guidance, Outlook, and Risks
Outlook and Pipeline
- Commercial Expansion: Amtagvi is approved in the U.S. and Canada. Approvals are pending in the UK and Australia (H1 2026) and Switzerland (2027). The company withdrew its initial EU Marketing Authorization Application (MAA) in July 2025 and plans to resubmit a centralized MAA in 2026.
- Clinical Pipeline:
- Frontline Melanoma: TILVANCE-301 Phase 3 trial (lifileucel + pembrolizumab) is ongoing.
- NSCLC: IOV-LUN-202 registrational trial (lifileucel monotherapy) is ongoing; preliminary data showed a 25.6% objective response rate (ORR).
- Sarcoma: Registrational trial for undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS) planned for Q2 2026.
- Liquidity: Management believes current capital ($303.0 million) is sufficient to fund operations for at least the next 12 months. An "at-the-market" offering program with Jefferies allows for the sale of up to $350.0 million of common stock.
Key Risks and Contingencies
- Profitability: The company has an accumulated deficit of $2.8 billion and expects to continue incurring losses as it scales commercialization and R&D.
- Manufacturing Complexity: TIL manufacturing is highly complex; failures in patient tissue collection or manufacturing can lead to expensed costs without revenue recognition.
- Regulatory Uncertainty: Risks include potential delays in global approvals, FDA requirements for confirmatory trials (TILVANCE-301), and the impact of the Inflation Reduction Act (IRA) on drug pricing.
- Legal Proceedings:
- Securities Litigation: Putative securities class actions and shareholder derivative lawsuits filed in May 2025 allege false/misleading statements regarding 2025 revenue forecasts. Cases were consolidated in December 2025.
- Derivative Suits: Ongoing litigation regarding director compensation (Shumacher case) and public offering disclosures (Ohio Laborers case).
Investor Verification Checklist
- Revenue Sustainability: Verify the correlation between Proleukin sales and Amtagvi infusions to assess the durability of revenue growth beyond initial distributor stocking.
- Manufacturing Yield: Monitor the rate of "out-of-specification" product and patient drop-offs, as these directly impact Cost of Sales and gross margins.
- EU Strategy: Confirm the timeline and strategy for the resubmission of the EU MAA following the July 2025 withdrawal.
- Cash Burn Rate: Track operating cash flow usage against the $303 million liquidity position to determine the necessity of future capital raises.
- Legal Exposure: Monitor the status of the consolidated securities class actions regarding 2025 revenue guidance for potential settlement costs or reputational impact.